A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis
BMC Rheumatology2018Vol. 2(1), pp. 13–13
Citations Over Time
Abstract
Clinicaltrials.gov, NCT01093885; March 2010.
Related Papers
- → Ambrisentan: a review of its use in pulmonary arterial hypertension(2017)43 cited
- → Ambrisentan for the management of pulmonary arterial hypertension(2008)33 cited
- → Ambrisentan and its role in the management of pulmonary arterialhypertension(2008)7 cited
- → AMBRISENTAN RESCUE THERAPY IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION WHO DISCONTINUED BOSENTAN OR SITAXSENTAN DUE TO LIVER FUNCTION ABNORMALITIES(2006)6 cited
- Pharmacology and clinical study of ambrisentan for treatment of pulmonary arterial hypertension(2008)